Eisai subsidiary names Antonio Gualberto as CMO

H3 Biomedicine, the USA-based precision medicine subsidiary of Japanese drugmaker Eisai (TYO: 4523), has named industry veteran Antonio Gualberto its chief medical officer (CMO).

Dr Gualberto’s most recent role was as co-founder and CMO at Californian company Kura Oncology (Nasdaq: KURA), where he led the discovery of the mechanism of action and clinical proof-of-concept of farnesyl transferase inhibitors as well as bringing a pipeline of new agents to the clinic.

Prior to this, Dr Gualberto held positions of increasing responsibility at EMD Serono, a subsidiary of Merck KGaA (MRK: DE), Takeda (TYO: 4502) and Pfizer (NYSE: PFE).